Repros Therapeutics may be worried about Androxal patent, TheStreet says

theflyonthewall.com

According to a report by TheStreet.com's Adam Feuerstein, Repros Therapeutics' court filing earlier today suggests the company is "more worried than it lets on about the risk its Androxal patent is invalidated."

View Comments (0)